Cargando…
Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies
Affibodies targeting amyloid-beta (Aβ) could potentially be used as therapeutic and diagnostic agents in Alzheimer’s disease (AD). Affibodies display suitable characteristics for imaging applications such as high stability and a short biological half-life. The aim of this study was to explore brain...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246779/ https://www.ncbi.nlm.nih.gov/pubmed/35538266 http://dx.doi.org/10.1007/s11095-022-03282-2 |
_version_ | 1784739029443411968 |
---|---|
author | Faresjö, Rebecca Lindberg, Hanna Ståhl, Stefan Löfblom, John Syvänen, Stina Sehlin, Dag |
author_facet | Faresjö, Rebecca Lindberg, Hanna Ståhl, Stefan Löfblom, John Syvänen, Stina Sehlin, Dag |
author_sort | Faresjö, Rebecca |
collection | PubMed |
description | Affibodies targeting amyloid-beta (Aβ) could potentially be used as therapeutic and diagnostic agents in Alzheimer’s disease (AD). Affibodies display suitable characteristics for imaging applications such as high stability and a short biological half-life. The aim of this study was to explore brain delivery and retention of Aβ protofibril-targeted affibodies in wild-type (WT) and AD transgenic mice and to evaluate their potential as imaging agents. Two affibodies, Z5 and Z1, were fused with the blood–brain barrier (BBB) shuttle single-chain variable fragment scFv8D3. In vitro binding of (125)I-labeled affibodies with and without scFv8D3 was evaluated by ELISA and autoradiography. Brain uptake and retention of the affibodies at 2 h and 24 h post injection was studied ex vivo in WT and transgenic (tg-Swe and tg-ArcSwe) mice. At 2 h post injection, [(125)I]I-Z5 and [(125)I]I-Z1 displayed brain concentrations of 0.37 ± 0.09% and 0.46 ± 0.08% ID/g brain, respectively. [(125)I]I-scFv8D3-Z5 and [(125)I]I-scFv8D3-Z1 showed increased brain concentrations of 0.53 ± 0.16% and 1.20 ± 0.35%ID/g brain. At 24 h post injection, brain retention of [(125)I]I-Z1 and [(125)I]I-Z5 was low, while [(125)I]I-scFv8D3-Z1 and [(125)I]I-scFv8D3-Z5 showed moderate brain retention, with a tendency towards higher retention of [(125)I]I-scFv8D3-Z5 in AD transgenic mice. Nuclear track emulsion autoradiography showed greater parenchymal distribution of [(125)I]I-scFv8D3-Z5 and [(125)I]I-scFv8D3-Z1 compared with the affibodies without scFv8D3, but could not confirm specific affibody accumulation around Aβ deposits. Affibody-scFv8D3 fusions displayed increased brain and parenchymal delivery compared with the non-fused affibodies. However, fast brain washout and a suboptimal balance between Aβ and mTfR1 affinity resulted in low intrabrain retention around Aβ deposits. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-022-03282-2. |
format | Online Article Text |
id | pubmed-9246779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-92467792022-07-02 Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies Faresjö, Rebecca Lindberg, Hanna Ståhl, Stefan Löfblom, John Syvänen, Stina Sehlin, Dag Pharm Res Research Paper Affibodies targeting amyloid-beta (Aβ) could potentially be used as therapeutic and diagnostic agents in Alzheimer’s disease (AD). Affibodies display suitable characteristics for imaging applications such as high stability and a short biological half-life. The aim of this study was to explore brain delivery and retention of Aβ protofibril-targeted affibodies in wild-type (WT) and AD transgenic mice and to evaluate their potential as imaging agents. Two affibodies, Z5 and Z1, were fused with the blood–brain barrier (BBB) shuttle single-chain variable fragment scFv8D3. In vitro binding of (125)I-labeled affibodies with and without scFv8D3 was evaluated by ELISA and autoradiography. Brain uptake and retention of the affibodies at 2 h and 24 h post injection was studied ex vivo in WT and transgenic (tg-Swe and tg-ArcSwe) mice. At 2 h post injection, [(125)I]I-Z5 and [(125)I]I-Z1 displayed brain concentrations of 0.37 ± 0.09% and 0.46 ± 0.08% ID/g brain, respectively. [(125)I]I-scFv8D3-Z5 and [(125)I]I-scFv8D3-Z1 showed increased brain concentrations of 0.53 ± 0.16% and 1.20 ± 0.35%ID/g brain. At 24 h post injection, brain retention of [(125)I]I-Z1 and [(125)I]I-Z5 was low, while [(125)I]I-scFv8D3-Z1 and [(125)I]I-scFv8D3-Z5 showed moderate brain retention, with a tendency towards higher retention of [(125)I]I-scFv8D3-Z5 in AD transgenic mice. Nuclear track emulsion autoradiography showed greater parenchymal distribution of [(125)I]I-scFv8D3-Z5 and [(125)I]I-scFv8D3-Z1 compared with the affibodies without scFv8D3, but could not confirm specific affibody accumulation around Aβ deposits. Affibody-scFv8D3 fusions displayed increased brain and parenchymal delivery compared with the non-fused affibodies. However, fast brain washout and a suboptimal balance between Aβ and mTfR1 affinity resulted in low intrabrain retention around Aβ deposits. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-022-03282-2. Springer US 2022-05-10 2022 /pmc/articles/PMC9246779/ /pubmed/35538266 http://dx.doi.org/10.1007/s11095-022-03282-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Paper Faresjö, Rebecca Lindberg, Hanna Ståhl, Stefan Löfblom, John Syvänen, Stina Sehlin, Dag Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies |
title | Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies |
title_full | Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies |
title_fullStr | Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies |
title_full_unstemmed | Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies |
title_short | Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-Aβ-Affibodies |
title_sort | transferrin receptor binding bbb-shuttle facilitates brain delivery of anti-aβ-affibodies |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246779/ https://www.ncbi.nlm.nih.gov/pubmed/35538266 http://dx.doi.org/10.1007/s11095-022-03282-2 |
work_keys_str_mv | AT faresjorebecca transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies AT lindberghanna transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies AT stahlstefan transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies AT lofblomjohn transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies AT syvanenstina transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies AT sehlindag transferrinreceptorbindingbbbshuttlefacilitatesbraindeliveryofantiabaffibodies |